MENU
+Compare
JANX
Stock ticker: NASDAQ
AS OF
Oct 17 closing price
Price
$26.76
Change
-$0.44 (-1.62%)
Capitalization
1.61B

JANX Janux Therapeutics Forecast, Technical & Fundamental Analysis

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer... Show more

JANX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for JANX with price predictions
Oct 16, 2025

JANX's RSI Indicator peaks and leaves overbought zone

The 10-day RSI Oscillator for JANX moved out of overbought territory on October 16, 2025. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 instances where the indicator moved out of the overbought zone. In of the 23 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where JANX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

JANX broke above its upper Bollinger Band on October 15, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for JANX entered a downward trend on October 06, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 08, 2025. You may want to consider a long position or call options on JANX as a result. In of 74 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for JANX just turned positive on October 08, 2025. Looking at past instances where JANX's MACD turned positive, the stock continued to rise in of 40 cases over the following month. The odds of a continued upward trend are .

JANX moved above its 50-day moving average on October 08, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for JANX crossed bullishly above the 50-day moving average on October 10, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where JANX advanced for three days, in of 238 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. JANX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.650) is normal, around the industry mean (24.455). P/E Ratio (0.000) is within average values for comparable stocks, (54.854). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.181). Dividend Yield (0.000) settles around the average of (0.037) among similar stocks. JANX's P/S Ratio (3333.333) is very high in comparison to the industry average of (352.090).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. JANX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
JANX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

JANX is expected to report earnings to rise 12.24% to -61 cents per share on November 11

Janux Therapeutics JANX Stock Earnings Reports
Q3'25
Est.
$-0.62
Q2'25
Missed
by $0.09
Q1'25
Missed
by $0.01
Q4'24
Beat
by $0.07
Q3'24
Missed
by $0.18
The last earnings report on August 07 showed earnings per share of -55 cents, missing the estimate of -46 cents. With 858.58K shares outstanding, the current market capitalization sits at 1.61B.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
10955 Vista Sorrento Parkway
Phone
+1 858 751-4493
Employees
64
Web
https://www.januxrx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ICERX47.520.17
+0.36%
NYLI Epoch International Chc SIMPLE Cl
TGSAX9.80N/A
N/A
Templeton Global Smaller Comp Adv
THISX84.91N/A
N/A
T. Rowe Price Health Sciences I
ADEIX17.66N/A
N/A
Ancora Dividend Value Equity I
BCSFX26.50-0.06
-0.23%
Brown Capital Mgmt Intl Sm Co Instl

JANX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, JANX has been loosely correlated with NUVL. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if JANX jumps, then NUVL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To JANX
1D Price
Change %
JANX100%
-3.82%
NUVL - JANX
47%
Loosely correlated
+0.87%
CGON - JANX
42%
Loosely correlated
-2.79%
SKYE - JANX
41%
Loosely correlated
-5.23%
APGE - JANX
41%
Loosely correlated
-4.39%
TERN - JANX
40%
Loosely correlated
+1.29%
More